



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 7, 2024

Andrew J. Hirsch  
President and Chief Executive Officer  
C4 Therapeutics, Inc.  
490 Arsenal Way, Suite 120  
Watertown, Massachusetts 02472

**Re: C4 Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed October 31, 2024**  
**File No. 333-282934**

Dear Andrew J. Hirsch:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Shoaib A. Ghias, Esq.